Next Article in Journal
Supercritical Carbon Dioxide as a Green Alternative to Achieve Drug Complexation with Cyclodextrins
Next Article in Special Issue
Early Renoprotective Effect of Ruxolitinib in a Rat Model of Diabetic Nephropathy
Previous Article in Journal
Designer Benzodiazepines: A Review of Toxicology and Public Health Risks
Review

Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease

1
Department of Nephrology, Clinic for Internal Medicine, University Medical Centre Maribor, Ljubljanska ulica 5, 2000 Maribor, Slovenia
2
Faculty of Medicine, University of Maribor, Taborska ulica 8, 2000 Maribor, Slovenia
3
Department of Dialysis, Clinic for Internal Medicine, University Medical Centre Maribor, Ljubljanska ulica 5, 2000 Maribor, Slovenia
*
Author to whom correspondence should be addressed.
Academic Editors: Swayam Prakash Srivastava and Surya Pandey
Pharmaceuticals 2021, 14(6), 561; https://0-doi-org.brum.beds.ac.uk/10.3390/ph14060561
Received: 25 May 2021 / Revised: 6 June 2021 / Accepted: 8 June 2021 / Published: 11 June 2021
(This article belongs to the Special Issue Advances in the Management of Diabetic Nephropathy)
Diabetes mellitus is a global health issue and main cause of chronic kidney disease. Both diseases are also linked through high cardiovascular morbidity and mortality. Diabetic kidney disease (DKD) is present in up to 40% of diabetic patients; therefore, prevention and treatment of DKD are of utmost importance. Much research has been dedicated to the optimization of DKD treatment. In the last few years, mineralocorticoid receptor antagonists (MRA) have experienced a renaissance in this field with the development of non-steroidal MRA. Steroidal MRA have known cardiorenal benefits, but their use is limited by side effects, especially hyperkalemia. Non-steroidal MRA still block the damaging effects of mineralocorticoid receptor overactivation (extracellular fluid volume expansion, inflammation, fibrosis), but with fewer side effects (hormonal, hyperkalemia) than steroidal MRA. This review article summarizes the current knowledge and newer research conducted on MRA in DKD. View Full-Text
Keywords: diabetic kidney disease; chronic kidney disease; mineralocorticoid receptor antagonists; spironolactone; eplerenone; apararenone; esaxerenone; finerenone diabetic kidney disease; chronic kidney disease; mineralocorticoid receptor antagonists; spironolactone; eplerenone; apararenone; esaxerenone; finerenone
MDPI and ACS Style

Vodošek Hojs, N.; Bevc, S.; Ekart, R.; Piko, N.; Petreski, T.; Hojs, R. Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease. Pharmaceuticals 2021, 14, 561. https://0-doi-org.brum.beds.ac.uk/10.3390/ph14060561

AMA Style

Vodošek Hojs N, Bevc S, Ekart R, Piko N, Petreski T, Hojs R. Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease. Pharmaceuticals. 2021; 14(6):561. https://0-doi-org.brum.beds.ac.uk/10.3390/ph14060561

Chicago/Turabian Style

Vodošek Hojs, Nina, Sebastjan Bevc, Robert Ekart, Nejc Piko, Tadej Petreski, and Radovan Hojs. 2021. "Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease" Pharmaceuticals 14, no. 6: 561. https://0-doi-org.brum.beds.ac.uk/10.3390/ph14060561

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop